Healthcare Facilities company Dr. Agarwals Health Care announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations of Rs 460 crore, growth of 31.9% YoY Revenue from Operations — India of Rs 413 crore, growth of 34.2% YoY Revenue from Mature Facilities of Rs 332 crore, growth of 28.9% YoY EBITDA of Rs 146 crore, growth of 15.1% YoY with EBITDA margin of 30.8% Profit after Tax of Rs 43 crore, growth of 3.0% YoY with PAT margin of 8.9% 236 Facilities as of March 31, 2025 17 Facilities have been added in Q4FY25 FY25 Financial Highlights: Revenue from Operations of Rs 1,711 crore; growth of 28.4% YoY Revenue from Operations — India of Rs 1,538 crore, growth of 32.4% YoY Revenue from Mature Facilities of Rs 1,206 crore, growth of 18.5% YoY Sale of Services contributed 79.0% and Sale of Products® contributed 21.0% to revenue from operations EBITDA of Rs 502 crore, growth of 23.6% YoY with EBITDA margins of 28.6% Profit after Tax of Rs 110 crore, growth of 16.1% YoY with profit after tax margins of 6.3% 59 Facilities were added in 12M FY2025 Of these 52 new Facilities have been set up and 7 Facilities have been acquired Performed 282,326 surgeries in 12M FY2025, growth of 28.0% YoY Commenting on Q4FY25 and Twelve Months ended March 31, 2025 results, Adil Agarwal, CEO, Dr. Agarwal’s Health Care, said: “We are pleased to announce our first annual results post-listing, recording a strong 31.9% revenue growth that reflects the sustained momentum in our operations. In India, we expanded our network from 165 to 218 centres, reinforcing our commitment to accessible, high-quality eye care. We remain committed to growth and see significant untapped potential in the Indian eye care market. Organized eye care chains like ours currently serve just 13—15% of the market, while the remaining 85-87% is fragmented across standalone hospitals, clinics, community- and trustrun institutions, and government facilities. This fragmentation presents a compelling opportunity for us to consolidate and scale. We aim to capitalize on this potential by increasing patient volumes per center, strengthening referral networks, executing targeted marketing initiatives, and maintaining an unwavering focus on patient satisfaction. With these growth drivers in place, we are committed to accelerating our financial performance in the years ahead and doing so by scaling smartly, growing responsibly, and leading purposefully.” Result PDF
Conference Call with Dr. Agarwals Health Care Ltd. Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Dr. Agarwals Health Care announced Q3FY25 results Revenue: Increased by 29.5% YoY, reaching Rs 430.7 crore compared to Rs 332.7 crore in Q3FY24. Other Income stood at Rs 12.7 crore in Q3FY25. EBITDA stood at Rs 118.9 crore in Q3FY25, a 26.3% increase from Rs 101.0 crore in Q3FY24. EBITDA margin was at 27.8% in Q3FY25, compared to 27.7% in Q3FY24. PBT stood at Rs 41.0 crore for Q3FY25, growing by 13.8% compared to Rs 36.0 crore in Q3FY24. PAT increased by 25.0%, reaching Rs 28.2 crore in Q3FY25 from Rs 22.6 crore in Q3FY24. Amar Agarwal, Chairman, said: " February 4, 2025, marked a remarkable achievement in our journey, with the successful listing of our company a testament to the dedication of our team and the trust of our patients.This milestone reinforces our commitment to delivering world-class eye care and advancing the field of vision health. We are also committed to driving research and embracing the latest technological advancements to offer the best possible treatments for all our patients. Furthermore, we aim to empower communities by increasing awareness of eye health, ensuring that eye care becomes accessible to everyone, no matter where they live. This is just the beginning, and together, we will continue to shine a brighter light on the future of eye care." Result PDF